Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinic… Read more
Herantis Pharma Oyj (HRTIS) - Total Liabilities
Latest total liabilities as of June 2025: €3.36 Million EUR
Based on the latest financial reports, Herantis Pharma Oyj (HRTIS) has total liabilities worth €3.36 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Herantis Pharma Oyj - Total Liabilities Trend (2011–2024)
This chart illustrates how Herantis Pharma Oyj's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Herantis Pharma Oyj Competitors by Total Liabilities
The table below lists competitors of Herantis Pharma Oyj ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gol Linhas Aéreas Inteligentes S.A
NYSE:GOLLQ
|
USA | $45.83 Billion |
|
Voip-Pal.Com Inc
OTCQB:VPLM
|
USA | $173.93K |
|
Old Mutual Ltd
JSE:OMU
|
South Africa | ZAC1.19 Trillion |
|
Brave C&H Supply Co Ltd
TWO:6538
|
Taiwan | NT$1.00 Billion |
|
Bukaka Teknik Utama Tbk Pt
JK:BUKK
|
Indonesia | Rp15.93 Trillion |
|
Wanhwa Enterprise Co
TW:2701
|
Taiwan | NT$1.39 Billion |
|
Eldeco Housing And Industries Limited
NSE:ELDEHSG
|
India | ₹5.51 Billion |
|
Blockchain Coinvestors Acquisition Corp I
NASDAQ:BCSA
|
USA | $16.90 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Herantis Pharma Oyj's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.71 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.92 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Herantis Pharma Oyj's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Herantis Pharma Oyj (2011–2024)
The table below shows the annual total liabilities of Herantis Pharma Oyj from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.81 Million | +39.36% |
| 2023-12-31 | €2.02 Million | -67.91% |
| 2022-12-31 | €6.29 Million | -1.12% |
| 2021-12-31 | €6.36 Million | -27.95% |
| 2020-12-31 | €8.83 Million | -4.19% |
| 2019-12-31 | €9.22 Million | +27.40% |
| 2018-12-31 | €7.24 Million | -3.28% |
| 2017-12-31 | €7.48 Million | -13.31% |
| 2016-12-31 | €8.63 Million | +6.69% |
| 2015-12-31 | €8.09 Million | +4.05% |
| 2014-12-31 | €7.77 Million | +208.39% |
| 2013-12-31 | €2.52 Million | +13.82% |
| 2012-12-31 | €2.21 Million | +15.35% |
| 2011-12-31 | €1.92 Million | -- |